Edition:
United Kingdom

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

20.70USD
25 Jun 2019
Change (% chg)

$-0.19 (-0.91%)
Prev Close
$20.89
Open
$20.76
Day's High
$20.76
Day's Low
$20.70
Volume
312
Avg. Vol
5,619
52-wk High
$27.38
52-wk Low
$13.18

Latest Key Developments (Source: Significant Developments)

BeyondSpring Enters Open Market Sale Agreements With Jefferies Relating To Ordinary Shares Offering Of Up To $30 Mln
Tuesday, 21 May 2019 

May 21 (Reuters) - BeyondSpring Inc ::BEYONDSPRING INC - ENTERED INTO AN OPEN MARKET SALE AGREEMENTS WITH JEFFERIES RELATING TO ORDINARY SHARES OFFERING OF UP TO $30 MILLION.  Full Article

BeyondSpring Inc Posts Qtrly Loss Per Share of $0.64
Tuesday, 30 Apr 2019 

April 30 (Reuters) - BeyondSpring Inc ::BEYONDSPRING PROVIDES BUSINESS UPDATE AND FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.BEYONDSPRING INC - QTRLY LOSS PER SHARE $0.64.BEYONDSPRING - ON TRACK TO SUBMIT NDAS FOR PLINABULIN TO CHINA'S NMPA FOR NON-SMALL CELL LUNG CANCER & CHEMOTHERAPY-INDUCED NEUTROPENIA IN Q4 2019.BEYONDSPRING INC - ON TRACK TO SUBMIT NDA FOR PLINABULIN TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR BOTH INDICATIONS IN 2020.  Full Article

BeyondSpring Announces Positive Pre-NDA Meeting With The U.S. FDA For Its Lead Asset, Plinabulin
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - BeyondSpring Inc ::BEYONDSPRING ANNOUNCES POSITIVE PRE-NDA MEETING WITH THE U.S. FDA FOR ITS LEAD ASSET, PLINABULIN.BEYONDSPRING INC - "WELL ON TRACK" TO SUBMIT NDA PACKAGES FOR PLINABULIN TO FDA.BEYONDSPRING INC - FOCUS OF MEETING WAS CONTENT OF CHEMISTRY, MANUFACTURING AND CONTROL (CMC) SECTIONS OF COMPANY'S PLANNED NDAS FOR PLINABULIN.  Full Article

Beyondspring - On Track To Submit An NDA To U.S. FDA For Treatment Of Cin
Thursday, 6 Dec 2018 

BeyondSpring Inc ::BEYONDSPRING ANNOUNCES PHASE 3 STUDY 105 OF ITS LEAD ASSET PLINABULIN FOR CHEMOTHERAPY-INDUCED NEUTROPENIA MEETS PRIMARY ENDPOINT AT INTERIM ANALYSIS.BEYONDSPRING INC - HAS NECESSARY DATA TO SUBMIT NDATO CHINA FOOD AND DRUG ADMINISTRATION.BEYONDSPRING - ON TRACK TO SUBMIT AN NDA TO U.S. FDA FOR TREATMENT OF CIN.  Full Article

Beyondspring Qtrly Loss Per Share $0.68
Tuesday, 3 Apr 2018 

April 3 (Reuters) - BeyondSpring Inc ::PROVIDES OPERATIONAL UPDATE AND FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.68.CASH AND CASH EQUIVALENTS WERE $30.6 MILLION AT DEC. 31, 2017, COMPARED TO $40.7 MILLION AT SEPT. 30, 2017.BELIEVES HAS SUFFICIENT CASH RESOURCES TO ADVANCE ONGOING CLINICAL TRIALS IN LATE 2018 OR EARLY 2019 AND FIRST HALF OF 2019.  Full Article

BeyondSpring Says Richard Brand Resigned As CFO
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Beyondspring Inc ::BEYONDSPRING SAYS RICHARD A. BRAND RESIGNED AS CHIEF FINANCIAL OFFICER OF CO EFFECTIVE AS OF FEBRUARY 20, 2018 - SEC FILING.BEYONDSPRING INC - AMY YANG WILL CONTINUE TO SERVE AS CO'S CONTROLLER WHILE ACTING AS INTERIM CFO.  Full Article

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018.  Full Article

Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Beyondspring Inc ::BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY.BEYONDSPRING INC - ‍EXPECT CFDA FILINGS OF FIRST NDAS FOR BOTH CIN AND NSCLC INDICATIONS POTENTIALLY IN 2018​.  Full Article

BeyondSpring qtrly loss per share $‍0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - BeyondSpring Inc :BeyondSpring reports third quarter 2017 operational and financial results.BeyondSpring Inc - qtrly loss per share $‍0.68​.  Full Article

BeyondSpring announces first patient enrolled in China
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - BeyondSpring Inc ::BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia.BeyondSpring-‍look forward to top line results, later in 2017, comparing plinabulin with pegfilgrastim from phase 2 portion of the phase 2/3 trial.  Full Article